Current status of metals as therapeutic targets in Alzheimer's disease.

Abstract

There is accumulating evidence that interactions between beta-amyloid and copper, iron, and zinc are associated with the pathophysiology of Alzheimer's disease (AD). A significant dyshomeostasis of copper, iron, and zinc has been detected, and the mismanagement of these metals induces beta-amyloid precipitation and neurotoxicity. Chelating agents offer a potential therapeutic solution to the neurotoxicity induced by copper and iron dyshomeostasis. Currently, the copper and zinc chelating agent clioquinol represents a potential therapeutic route that may not only inhibit beta-amyloid neurotoxicity, but may also reverse the accumulation of neocortical beta-amyloid. A Phase II double-blind clinical trial of clioquinol with B12 supplementation will be published soon, and the results are promising. This article summarizes the role of transition metals in amyloidgenesis and reviews the potential promise of chelation therapy as a treatment for AD.

1 Figure or Table

050100150'04'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

713 Citations

Semantic Scholar estimates that this publication has 713 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Finefrock2003CurrentSO, title={Current status of metals as therapeutic targets in Alzheimer's disease.}, author={Anne E Finefrock and Ashley I. Bush and P. Murali Doraiswamy}, journal={Journal of the American Geriatrics Society}, year={2003}, volume={51 8}, pages={1143-8} }